LB Pharmaceuticals (LBRX) Q4 2025 earnings summary

Executive summary

• Achieved positive Phase 2 results for LB-102 in acute schizophrenia, supporting further development in neuropsychiatric disorders.

• Advanced LB-102 into pivotal Phase 3 (NOVA-2) for schizophrenia and Phase 2 (ILLUMINATE-1) for bipolar depression; planned Phase 2 for adjunctive MDD in 2027.

• Completed successful IPO in September 2025, raising $327.8 million, and secured $100 million in private placement in February 2026.

• Strengthened leadership with new board and executive appointments to support clinical and corporate strategy.

Financial highlights

• Research & development expenses for Q4 2025 were $8.5M, up from $0.4M in Q4 2024, due to new trial start-up costs.

• General & administrative expenses for Q4 2025 were $5.4M, slightly up from $5.2M in Q4 2024.

• Net loss for Q4 2025 was $11.5M, compared to $5.1M in Q4 2024; full-year 2025 net loss was $25.2M, down from $63.1M in 2024.

• Cash, cash equivalents, and marketable securities totaled $295.2M as of December 31, 2025.

Outlook and guidance

• Current cash position, including recent private placement, expected to fund operations into Q2 2029.

• Topline data from Phase 3 NOVA-2 in schizophrenia expected in H2 2027; Phase 2 ILLUMINATE-1 in bipolar depression expected Q1 2028; Phase 2 adjunctive MDD trial topline data expected H1 2029.